NASDAQ: PBMPsyence Biomedical Ltd Stock
$5.14+0.18 (+3.63%)
Updated Jul 11, 2025
PBM Price
$5.14
Fair Value Price
-$1.08
Market Cap
$2.92M
52 Week Low
$2.92
52 Week High
$699.19
P/E
0.98x
P/B
0.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$1.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$4M
Beta
0.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PBM Overview
Newcourt Acquisition Corp. is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets digital financial services and fintech companies with exposure to emerging markets. Newcourt Acquisition founded in 2021 and is headquartered in Oakland, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PBM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PBM
Ranked#140 of 475
Ranked#140 of 475
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.39 | A | |
| $8.80 | A | |
| $44.86 | A |
Be the first to know about important PBM news, forecast changes, insider trades & much more!
PBM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PBM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBM ($5.14) is overvalued by 575.7% relative to our estimate of its Fair Value price of -$1.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PBM ($5.14) is not significantly undervalued (575.7%) relative to our estimate of its Fair Value price of -$1.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PBM was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PBM due diligence checks available for Premium users.
Valuation
PBM fair value
Fair Value of PBM stock based on Discounted Cash Flow (DCF)
Price
$5.14
Fair Value
-$1.08
Undervalued by
576.16%
PBM ($5.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PBM ($5.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PBM was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PBM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.98x
Industry
-154.99x
Market
30.99x
PBM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PBM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PBM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
4.62x
PBM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PBM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PBM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.3M
Liabilities
$594.4k
Debt to equity
0.09
PBM's short-term assets ($6.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBM's short-term assets ($6.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PBM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PBM vs Biotech Stocks
Psyence Biomedical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.